|Bid||0.6600 x 1000|
|Ask||0.7999 x 1900|
|Day's Range||0.6701 - 0.7200|
|52 Week Range||0.6100 - 4.9000|
|PE Ratio (TTM)||-0.54|
|Earnings Date||Nov 7, 2017 - Nov 13, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
SAN DIEGO, Sept. 20, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced the expansion and strengthening of its Board of Directors with the appointment of Athena Countouriotis, M.D. Dr. Countouriotis brings significant experience leading clinical development programs, from preclinical through clinical stages, and approval. Over the course of her career, she has been involved in multiple clinical programs, with a focus within oncology, both hematologic and solid tumor indications, that have supported regulatory approvals in the U.S. and Europe. Dr. Countouriotis currently serves as Senior Vice President, Chief Medical Officer at Adverum Biotechnologies.
TrovaGene Inc (NASDAQ:TROV), a pharmaceuticals, biotechnology and life sciences company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM in the overRead More...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to TrovaGene, Inc. Here are 5 ETFs with the largest exposure to TROV-US. Comparing the performance and risk of TrovaGene, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)